Glucagon-like peptide-1 (GLP-1) receptor agonists aka the -tides, GLP analogs, incretin mimetics *The FDA has approved the use of -glutides to reduce the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Eli Lilly's Orforglipron (Not Yet Approved - Expected March 2026): According to CNN, Eli Lilly's experimental oral drug showed 11% mean weight loss over 72 weeks on its highest dose in clinical trials
Unregulated glucose uptake results in excess reactive oxygen species production [23]
These are numbers the weight loss field had never seen from a single intervention before
What they're saying: Chipotle cites IFIC data showing high-protein diets have been the top U.S
The first swipe of Keys Soulcare lip balm went on sheer but perceptible, even for our testers with dark lip tones (those same folks found that some other pigmented balms all but disappeared)